Scholarly Index
Mario Campone
Institut de Cancérologie de l'Ouest; 51,500 total citations; 860 total publications; best world rank #27
Institut de Cancérologie de l'Ouest
51,500Total citations
860Total publications
92H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Cancer Treatment and Pharmacology | Lifetime | 71 | FR 5 | 99.73 |
| Advanced Breast Cancer Therapies | Lifetime | 27 | FR 2 | 99.66 |
| HER2/EGFR in Cancer Research | Lifetime | 84 | FR 2 | 99.57 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 105 | FR 3 | 99.01 |
| Breast Cancer Treatment Studies | Lifetime | 246 | FR 10 | 99.19 |
| Cancer Genomics and Diagnostics | Lifetime | 926 | FR 44 | 98.39 |
| Peptidase Inhibition and Analysis | Lifetime | 737 | FR 27 | 97.62 |
| Cancer Cells and Metastasis | Lifetime | 738 | FR 22 | 97.13 |
| PARP inhibition in cancer therapy | Lifetime | 732 | FR 37 | 92.54 |
| Chemotherapy-related skin toxicity | Lifetime | 804 | FR 35 | 81.70 |
| Advanced Breast Cancer Therapies | 2021-2025 | 35 | FR 2 | 99.28 |
| HER2/EGFR in Cancer Research | 2021-2025 | 69 | FR 3 | 98.84 |
| Breast Cancer Treatment Studies | 2021-2025 | 135 | FR 8 | 98.33 |
| Cancer Treatment and Pharmacology | 2021-2025 | 98 | FR 11 | 98.09 |
| Estrogen and related hormone effects | 2021-2025 | 893 | FR 38 | 71.50 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 528 | FR 16 | 69.58 |